Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ImmunoPrecise Antibodies Ltd
IPA | US
0.54
USD-0.00
-0.89%
IPA | US
About ImmunoPrecise Antibodies Ltd
Sector
Healthcare
Industry
Biotechnology
Earnings date
31/07/2024
As of date
21/10/2024
Close
0.54
Open
0.55
High
0.55
Low
0.51
ImmunoPrecise Antibodies Ltd. together with its subsidiaries engages in antibody production and provision of related services in the United States Canada Europe Australia and internationally. The company offers a range of antibodies enzymes enzyme activity assays arthritis animal products proteins deiminated proteins organoid growth factors and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling design and manufacturing; B cell sorting screening and sequencing; custom immune and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific tri-specific VHH and VNAR (shark) antibody manufacturing; DNA cloning protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed high-throughput screening and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria Canada.
View LessIPA | US
Risk
54.5
Sharpe
-0.64
Luna's Score
36/100
Recommendation
Sell
Luna says (IPA | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
32.3%1 month
54.5%3 months
116.1%6 months
89.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.63
Debt to equity
0.49
Debt to assets
0.27
Ent. to EBITDA
-4.68
Ent. to rev.
1.36
PEG
-
Other Fundamentals
EBITDA
-11.51M
MarketCap
14.94M
MarketCap(USD)
14.94M
Div. yield
-
Op. margin
-86.23
Erngs. growth
-
Rev. growth
-7.50
Ret. on equity
-64.04
Short ratio
0.72
Short perc.
0.66
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.20
Range1M
0.23
Range3M
0.58
Volumes: Market Activity
Rel. volume
0.46
Price X volume
69.97K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -4.68 | - | Cheaper |
| Ent. to Revenue | 1.36 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.63 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 116.09 | - | Riskier |
| Debt to Equity | 0.49 | -1.23 | Expensive |
| Debt to Assets | 0.27 | 0.25 | Par |
| Market Cap | 14.94M | - | Emerging |
